<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882854</url>
  </required_header>
  <id_info>
    <org_study_id>160282</org_study_id>
    <nct_id>NCT02882854</nct_id>
  </id_info>
  <brief_title>Guanfacine for PONV and Pain After Sinus Surgery</brief_title>
  <official_title>Guanfacine for PONV and Pain After Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) and pain are the most common causes of Post
      Anesthesia Care Unit (PACU) discharge delay, with untreated PONV occurring in 20-30% of
      post-surgical patients. The effect of guanfacine (GF) administration on pain and nausea
      scores will be assessed with two groups. One group will receive 1 mg of GF to take orally and
      the other group will receive a similar appearing placebo (containing no drug) to take orally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain after surgery is commonly treated with narcotics which can potentiate PONV, further
      delaying PACU discharge. In multiple studies, alpha-2 agonists such as clonidine and
      dexmedetomidine reduce both the incidence of PONV and post-op pain, as well as requirements
      for postoperative analgesics. These actions are mediated via central alpha-2A receptors
      (A2AR). Of the A2AR agonists, guanfacine, though a weak antihypertensive agent, has the
      highest selectivity for the A2AR, but to date is untested for its potential to treat either
      PONV or post-operative pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of PONV Score of assessments done at 15, 30, and 60 minutes after arrival in PACU using 11-point nausea scale (nVRS)</measure>
    <time_frame>60 minutes after arriving in PACU</time_frame>
    <description>Comparison of PONV Score of assessments done at 15, 30, and 60 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative nausea assessment using 11-point nausea scale (nVRS)</measure>
    <time_frame>24 hours post op</time_frame>
    <description>PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum postoperative pain assessment using 11-point Visual/Verbal Analog (VAS)</measure>
    <time_frame>15, 30, 60 minutes after arriving in PACU</time_frame>
    <description>Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain assessment using 11-point Visual/Verbal Analog (VAS)</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total narcotic requirement in PACU</measure>
    <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
    <description>Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of doses of PONV treatment administered in PACU</measure>
    <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Length of Stay in minutes</measure>
    <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>Patients will receive 1 mg of guanfacine to take orally.</description>
    <arm_group_label>Guanfacine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VUMC patients undergoing sinus surgery in MCE OR

        Exclusion Criteria:

          -  Inability to read and freely consent

          -  Patients who take alpha-2 agonists routinely (guanfacine, clonidine, tizanidine)

          -  Patients undergoing sinus surgery planned for greater than 3 hours

          -  Patients with significant pre-existing pain, on chronic pain (opioid, methadone)
             therapy, severe fibromyalgia or other pre-existing pain condition in any body part

          -  Patients with preoperative nausea/vomiting at baseline.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen T Harvey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen T Harvey, MD</last_name>
    <phone>615-936-3198</phone>
    <email>stephen.harvey@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail Mayo, RN</last_name>
    <phone>615-936-1705</phone>
    <email>gail.mayo@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth. 2002 Sep;89(3):409-23. Review.</citation>
    <PMID>12402719</PMID>
  </reference>
  <reference>
    <citation>Luttinger D, Ferrari R, Perrone MH, Haubrich DR. Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia. J Pharmacol Exp Ther. 1985 Mar;232(3):883-9.</citation>
    <PMID>2857790</PMID>
  </reference>
  <reference>
    <citation>Yamadera H, Ferber G, Matejcek M, Pokorny R. Electroencephalographic and psychometric assessment of the CNS effects of single doses of guanfacine hydrochloride (Estulic) and clonidine (Catapres). Neuropsychobiology. 1985;14(2):97-107.</citation>
    <PMID>3911096</PMID>
  </reference>
  <reference>
    <citation>Connor DF, Arnsten AF, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opin Pharmacother. 2014 Aug;15(11):1601-10. doi: 10.1517/14656566.2014.930437. Epub 2014 Jul 3. Review.</citation>
    <PMID>24992513</PMID>
  </reference>
  <reference>
    <citation>Massad IM, Mohsen WA, Basha AS, Al-Zaben KR, Al-Mustafa MM, Alghanem SM. A balanced anesthesia with dexmedetomidine decreases postoperative nausea and vomiting after laparoscopic surgery. Saudi Med J. 2009 Dec;30(12):1537-41.</citation>
    <PMID>19936416</PMID>
  </reference>
  <reference>
    <citation>Kamibayashi T, Hayashi Y, Mammoto T, Yamatodani A, Sumikawa K, Yoshiya I. Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. Anesthesiology. 1995 Nov;83(5):992-9.</citation>
    <PMID>7486186</PMID>
  </reference>
  <reference>
    <citation>Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. 1984 Mar;319(1):69-101. Review.</citation>
    <PMID>6324960</PMID>
  </reference>
  <reference>
    <citation>Giovannoni MP, Ghelardini C, Vergelli C, Dal Piaz V. Alpha2-agonists as analgesic agents. Med Res Rev. 2009 Mar;29(2):339-68. doi: 10.1002/med.20134. Review.</citation>
    <PMID>18680204</PMID>
  </reference>
  <reference>
    <citation>Aghajanian GK, Wang YY. Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology. 1987 Jul;26(7B):793-9. Review.</citation>
    <PMID>2443865</PMID>
  </reference>
  <reference>
    <citation>Ittermann T, Völzke H, Baumeister SE, Appel K, Grabe HJ. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol. 2015 Sep;50(9):1417-25. doi: 10.1007/s00127-015-1043-0. Epub 2015 Mar 17.</citation>
    <PMID>25777685</PMID>
  </reference>
  <reference>
    <citation>Baser E, Togrul C, Ozgu E, Esercan A, Caglar M, Gungor T. Effect of pre-procedural state-trait anxiety on pain perception and discomfort in women undergoing colposcopy for cervical cytological abnormalities. Asian Pac J Cancer Prev. 2013;14(7):4053-6.</citation>
    <PMID>23991951</PMID>
  </reference>
  <reference>
    <citation>Benarroch EE. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology. 2009 Nov 17;73(20):1699-704. doi: 10.1212/WNL.0b013e3181c2937c.</citation>
    <PMID>19917994</PMID>
  </reference>
  <reference>
    <citation>Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995 Mar;14(3):477-85. Review.</citation>
    <PMID>7695894</PMID>
  </reference>
  <reference>
    <citation>Wang M, Gamo NJ, Yang Y, Jin LE, Wang XJ, Laubach M, Mazer JA, Lee D, Arnsten AF. Neuronal basis of age-related working memory decline. Nature. 2011 Jul 27;476(7359):210-3. doi: 10.1038/nature10243.</citation>
    <PMID>21796118</PMID>
  </reference>
  <reference>
    <citation>Goldman-Rakic PS. Circuitry of the frontal association cortex and its relevance to dementia. Arch Gerontol Geriatr. 1987 Sep;6(3):299-309. Review.</citation>
    <PMID>3318747</PMID>
  </reference>
  <reference>
    <citation>Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 Jan;34(1):50-4.</citation>
    <PMID>7860456</PMID>
  </reference>
  <reference>
    <citation>Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85(1):45-58. Epub 2012 Mar 29. Review.</citation>
    <PMID>22461743</PMID>
  </reference>
  <reference>
    <citation>Zhao X, Tong D, Long B, Wu X. [Effects of different doses of dexmedetomidine on the recovery quality from general anesthesia undergoing thyroidectomy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Apr;26(4):239-43. doi: 10.3760/cma.j.issn.2095-4352.2014.04.008. Chinese.</citation>
    <PMID>24709495</PMID>
  </reference>
  <reference>
    <citation>Blaudszun G, Lysakowski C, Elia N, Tramèr MR. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb. Review.</citation>
    <PMID>22546966</PMID>
  </reference>
  <reference>
    <citation>Lin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, Fan SZ. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009 Jan;102(1):117-22. doi: 10.1093/bja/aen320. Epub 2008 Nov 5.</citation>
    <PMID>18987053</PMID>
  </reference>
  <reference>
    <citation>Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth. 2006 Jul;53(7):646-52.</citation>
    <PMID>16803911</PMID>
  </reference>
  <reference>
    <citation>Ozkose Z, Demir FS, Pampal K, Yardim S. Hemodynamic and anesthetic advantages of dexmedetomidine, an alpha 2-agonist, for surgery in prone position. Tohoku J Exp Med. 2006 Oct;210(2):153-60.</citation>
    <PMID>17023769</PMID>
  </reference>
  <reference>
    <citation>Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, Skrivanek G, Macaluso A, Shah M, Provost DA. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg. 2008 Jun;106(6):1741-8. doi: 10.1213/ane.0b013e318172c47c.</citation>
    <PMID>18499604</PMID>
  </reference>
  <reference>
    <citation>Rago R, Forfori F, Materazzi G, Abramo A, Collareta M, Miccoli P, Giunta F. Evaluation of a preoperative pain score in response to pressure as a marker of postoperative pain and drugs consumption in surgical thyroidectomy. Clin J Pain. 2012 Jun;28(5):382-6. doi: 10.1097/AJP.0b013e3182326495.</citation>
    <PMID>22001665</PMID>
  </reference>
  <reference>
    <citation>Hicks JA, Jenkins JG. The measurement of preoperative anxiety. J R Soc Med. 1988 Sep;81(9):517-9.</citation>
    <PMID>3184108</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008 Dec;61(12):1234-40. doi: 10.1016/j.jclinepi.2008.01.006. Epub 2008 Jul 10.</citation>
    <PMID>18619805</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700.</citation>
    <PMID>10485781</PMID>
  </reference>
  <reference>
    <citation>Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003 Jun;98(6):1415-21.</citation>
    <PMID>12766651</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Stephen Harvey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

